INCY

Incyte
Biotechnology · Health Care · as of 2026-11-20
Last close
$115.45
-0.4% on the session
1-year return
+13.9%
+18.8% over six months
Volatility
33.0%
annualized, trailing year
Max drawdown
-18.3%
worst peak to trough, 1y
What the numbers say

Incyte is a biotechnology name in the health care sector. Over the past year it returned +13.9%, against -9.8% over three months and -1.3% over one. It trades 5.6% above its 200-day average, so the longer trend is confirming recent strength. Annualized volatility of 33.0% is above the market's typical range.

Its worst peak-to-trough decline over the year was -18.3%, and it has traded a median $179M a day, the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate 0.20 with the S&P 500 proxy, so it has been moving substantially on its own.

Where it ranks
Within Health Care#46 of 59
Stronger than 22% of its sector on the momentum profile
Across the whole index#254 of 497

How INCY scores on all four profiles

Its standing on steadiness, defensiveness and rebound, plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 7 others in Biotechnology.

Start a free 7-day trial
Full metrics
1 day-0.4%
1 week-4.6%
1 month-1.3%
3 months-9.8%
6 months+18.8%
1 year+13.9%
12-1 momentum+15.4%
Volatility (1y, annualized)33.0%
Max drawdown (1y)-18.3%
Distance vs 200-day average+5.6%
Return per unit of risk0.42
Median daily dollar volume$179M
Free newsletter

Get INCY when it shows up in a ranking

Two editions a weekday, free, ranked lists built from this same data, on whatever the market is talking about.

Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.